$EAPH AH news:
Easton Pharmaceuticals Announces Neil Mellor as Senior Consultant, Chief Operations Officer
Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, announced today that Mr. Neil Mellor will join the company as Senior Consultant, Chief Operations Officer. Mr. Mellor has over 25 years of experience in the pharmaceutical industry, both in Canada and Europe. The majority of Mr. Mellor’s background is in sales, marketing and business development for companies such as Merck, Pharmacia (now Pfizer), and Solvay Pharma (now Abbott Laboratories).
Over the past 10 years, Mr. Mellor has been Associate Director of Business Development at Solvay Pharma. In addition, Mr. Mellor served as President of the Canadian Healthcare Licensing Association (CHLA) from 2007 to 2008 and remains an active member of the Board of the CHLA. Mr. Mellor is currently the President of Global Health Link, a healthcare consulting company serving Canadian and US clients. We are especially pleased to have such an accomplished professional as Mr. Mellor on board to help with our future plans for our products, beginning with our lead product VIORRATM,” commented Mr. John Adams, of Easton Pharmaceuticals’. "Mr. Mellor’s vast experience in marketing and licensing will help us navigate the sometimes uncertain waters of the different markets Easton Pharmaceuticals is considering, and will help us focus on the design and execution of key business activities which will enrich our pending commercialization efforts.”
About Easton Pharmaceuticals Inc
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding numbers of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins. The world market for these conditions is in excess of US$10 billion.
The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals’ flagship product, VIORRA, is an over-the-counter aid to help restore and improve vaginal moisture and elasticity which plays an important role in women’s sexual desire and arousal , FSAD (Female Sexual Arousal Disorder). The world market for products which treat this disorder is in excess of US$2 billion. VIORRA is a topical, daily-use product classified by the US Food and Drug Administration (FDA) as containing Generally Recognized as Safe ingredients.
For more information, visit http://www.eastonpharma.com or http://www.ashleybiomedical.com
Contact:
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email and Media Relations: info@lamindustries.com
Email and Media Relations: info@ashleybiomedical.com
Easton Pharmaceuticals Inc.
Dragoslav Milanovic, CEO
+1-416-619-0291
+1-347-284-0192
or
Media Relations:
info@lamindustries.com
or
info@ashleybiomedical.com
(0)
(0)
